hepatitis B

Recent Articles

RELATED ARTICLES

  1. The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand.
    Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
    1672.HK
  2. Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
  3. GenScript losses shrink on strong growth for cancer cell therapy 
    1548.HK
  4. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  5. Akeso marks profit milestone with swift rights issue
    9926.HK
  6. Test results for new cancer drug take Akeso investors on wild ride
    9926.HK
  7. Everest reaches new heights on growing drug sales
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva